Clinical Trials Logo

Clinical Trial Summary

To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will receive Gum Arabic and the other half will receive placebo


Clinical Trial Description

Polymerized hemoglobin is injurious to the red cell membrane, resulting in oxidative damage in sickle cell disease . Fetal hemoglobin is protective against sickling and its decrease is associated with vaso-occlusive crisis . Gum Arabic is soluble fibers with prebiotic properties. It increased the level of serum butyrate which is short chain fatty acid. The latter proved to serve as fetal hemoglobin inducing agent both in vivo and in vitro study. And also has strong anti-inflammatory properties. So our aim to test whether oral digestion of Gum Arabic will induce fetal hemoglobin among sickle cell pediatric patients ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04191213
Study type Interventional
Source Al-Neelain University
Contact Dalya MM Abdelmaged, MBBS
Phone 00249126831595
Email dalya.alfeel@gmail.com
Status Recruiting
Phase Phase 2/Phase 3
Start date February 15, 2020
Completion date July 15, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06387758 - Low Systemic/High Local Exercise Load in Peds SCD N/A
Completed NCT04579926 - PINPOINT: Gaming Technology for SCD Pain N/A
Completed NCT03632876 - Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD N/A
Recruiting NCT05285917 - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa Phase 3
Completed NCT04301336 - Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Phase 2/Phase 3
Completed NCT03176849 - A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Phase 4
Active, not recruiting NCT04750707 - Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II ) Phase 3
Recruiting NCT05018728 - The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia Phase 2
Completed NCT04844099 - Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia Phase 3
Enrolling by invitation NCT03948867 - Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE) Phase 2
Completed NCT04800809 - The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria